These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25575111)

  • 1. Biomarkers in nonalcoholic fatty liver disease.
    Neuman MG; Cohen LB; Nanau RM
    Can J Gastroenterol Hepatol; 2014 Dec; 28(11):607-18. PubMed ID: 25575111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    Makri ES; Evripidou K; Polyzos SA
    J Gastroenterol Hepatol; 2024 May; 39(5):806-817. PubMed ID: 38238084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.
    Niu L; Geyer PE; Wewer Albrechtsen NJ; Gluud LL; Santos A; Doll S; Treit PV; Holst JJ; Knop FK; Vilsbøll T; Junker A; Sachs S; Stemmer K; Müller TD; Tschöp MH; Hofmann SM; Mann M
    Mol Syst Biol; 2019 Mar; 15(3):e8793. PubMed ID: 30824564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest.
    García-Carretero R; Holgado-Cuadrado R; Barquero-Pérez Ó
    Entropy (Basel); 2021 Jun; 23(6):. PubMed ID: 34204225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease?
    Dasarathy S
    Hepatology; 2014 Jul; 60(1):22-5. PubMed ID: 24644076
    [No Abstract]   [Full Text] [Related]  

  • 6. Vascular adhesion protein 1 in nonalcoholic steatohepatitis: a novel biomarker?
    Torok NJ
    Hepatology; 2015 Oct; 62(4):1313-5. PubMed ID: 26084585
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers of Hepatic Toxicity: An Overview.
    Thakur S; Kumar V; Das R; Sharma V; Mehta DK
    Curr Ther Res Clin Exp; 2024; 100():100737. PubMed ID: 38860148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioneering the path to NASH biomarker approval.
    Krag A; Rinella ME
    Nat Med; 2023 Oct; 29(10):2416-2417. PubMed ID: 37679432
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarkers in Fatty Liver Disease-Here is the Skinny.
    Ravanbakhsh N; Kohli R
    J Clin Exp Hepatol; 2021; 11(6):637-640. PubMed ID: 34866840
    [No Abstract]   [Full Text] [Related]  

  • 10. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.
    Gorden DL; Myers DS; Ivanova PT; Fahy E; Maurya MR; Gupta S; Min J; Spann NJ; McDonald JG; Kelly SL; Duan J; Sullards MC; Leiker TJ; Barkley RM; Quehenberger O; Armando AM; Milne SB; Mathews TP; Armstrong MD; Li C; Melvin WV; Clements RH; Washington MK; Mendonsa AM; Witztum JL; Guan Z; Glass CK; Murphy RC; Dennis EA; Merrill AH; Russell DW; Subramaniam S; Brown HA
    J Lipid Res; 2015 Mar; 56(3):722-736. PubMed ID: 25598080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?
    Birerdinc A; Younossi Z
    J Hepatol; 2015 Apr; 62(4):761-2. PubMed ID: 25602593
    [No Abstract]   [Full Text] [Related]  

  • 15. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
    Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
    Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathobiology of liver fibrosis: a translational success story.
    Lee YA; Wallace MC; Friedman SL
    Gut; 2015 May; 64(5):830-41. PubMed ID: 25681399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A; Wong RJ; Harrison SA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
    Noureddin M; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.